ESPRIT Study in Hypogonadal Men
NCT01143818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1053
Last updated 2011-10-17
Summary
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
Conditions
- Hypogonadism
Interventions
- DRUG
-
AndroGel (testosterone gel) 1%
AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
Sponsors & Collaborators
-
Fovea
collaborator OTHER - lead INDUSTRY
Principal Investigators
-
Michael Miller, PharmD · Abbott
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-12-31
- Primary Completion
- 2010-08-31
- Completion
- 2010-08-31
Countries
- Canada
- Croatia
- Germany
- Kuwait
- Romania
- Russia
- Saudi Arabia
- Slovenia
- United Arab Emirates
Study Locations
More Related Trials
-
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males
NCT02149264 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
NCT01464879 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
NCT01703741 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
NCT01386606 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone
NCT00522431 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
NCT01893281 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
NCT01993212 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
NCT04274894 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.
NCT01346319 ·Status: COMPLETED ·Phase: PHASE1
-
The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery
NCT00413244 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
NCT00141492 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill
NCT05825092 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients
NCT03678233 ·Status: UNKNOWN ·Phase: PHASE2
-
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
NCT00853697 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
NCT00998933 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
NCT02110368 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males
NCT01133548 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
NCT01993225 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
NCT01403116 ·Status: COMPLETED ·Phase: PHASE3
-
The Testosterone Trials in Older Men
NCT00799617 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
NCT01699178 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
NCT01235754 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier
NCT01130298 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
NCT00365794 ·Status: COMPLETED ·Phase: PHASE2
-
A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
NCT01386567 ·Status: COMPLETED ·Phase: PHASE2